Moderna increased its revenue outlook for 2026, now expecting growth between 15% and 25%, up from a previous forecast of 10%. The company, known for its mRNA COVID-19 vaccine Spikevax, cited strong sales as the reason for the optimistic update. This improved forecast signals confidence in Moderna's continued market performance and could positively impact investor sentiment.
Moderna's market capitalization stands at $96.40 billion as of November 6, 2026, 19:31 WIB, reflecting strong investor interest following the company's raised sales outlook. The stock price on Pluang is $255.00, up 5.61% for the day, with a trading volume of 11,879,068 shares. Buy orders dominate at 68%, indicating positive sentiment among Pluang users.
Moderna exceeded third-quarter revenue and earnings expectations, reporting $1.31 billion in revenue and 38 cents earnings per share, compared to analyst estimates of $885.1 million and a loss of $1.25 per share. The company raised its 2026 revenue g...
On November 6, Moderna, Humana, and Elanco will release earnings reports that could impact their stock rallies. Humana's Medicare Advantage update is crucial for retirees, with a focus on medical costs and membership trends. Elanco faces supply chall...
Moderna's stock is rated Strong Sell at $220.83, with a valuation around $60 per share, implying a 73% downside. This is despite promising Phase 3 melanoma trial results showing a 42% reduction in relapse or death when using intismeran with Keytruda....
Moderna's stock rose 5% ahead of its earnings report, continuing a strong 685% gain this year, driven by its mRNA vaccine focus and oncology pipeline. Pfizer's shares fell 0.8% despite beating Q3 revenue estimates and raising its 2026 guidance, as CO...
